13,500
Participants
Start Date
June 4, 2022
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2028
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
placebo
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
RECRUITING
Lianyuan Center for Disease Control and Prevention, Lianyuan
RECRUITING
Qiyang Center for Disease Control and Prevention, Wuxi
NOT_YET_RECRUITING
Hezhou Center for Disease Control and Prevention, Hezhou
NOT_YET_RECRUITING
Hechi Yizhou District Center for Disease Control and Prevention, Hechi
NOT_YET_RECRUITING
Mianyang Youxian District Center for Disease Control and Prevention, Mianyang
NOT_YET_RECRUITING
Neijiang Shizhong District Center for Disease Control and Prevention, Neijiang
NOT_YET_RECRUITING
Yongji Center for Disease Control and Prevention, Yongji
NOT_YET_RECRUITING
Yuanqu Center for Disease Control and Prevention, Yuncheng
Chengdu Institute of Biological Products Co.,Ltd.
INDUSTRY
Simoon Record Pharma Information Consulting Co., Ltd.
INDUSTRY
Beijing Kantorico Statistical Technology Co., Ltd.
UNKNOWN
Guangxi Center for Disease Control and Prevention
OTHER_GOV
Hunan Provincial Center for Disease Control and Prevention
OTHER
Sichuan Center for Disease Control and Prevention
OTHER_GOV
Centers for Disease Control and Prevention, China
OTHER_GOV
National Vaccine and Serum Institute, China
INDUSTRY